{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:37:23Z","timestamp":1789699043193,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This meta-analysis aimed to compare the effects of prasugrel and ticagrelor on high (HTPR) and low on-treatment platelet reactivity (LTPR) in patients with acute coronary syndrome (ACS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible studies were retrieved from PubMed, Embase, and the Cochrane Library. HTPR and LTPR were evaluated on the basis of the vasodilator-stimulated phosphoprotein platelet reactivity index (VASP-PRI) and P2Y12 reaction units (PRUs). HTPR and LTPR were analyzed using risk ratios (RRs) and their 95% confidence intervals (CIs). Weighted mean difference (WMD) and 95% CI were used to calculate the pooled effect size of platelet reactivity (PR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fourteen eligible studies were obtained, which included 2629 patients treated with ticagrelor (<jats:italic>n<\/jats:italic>\u2009=\u20091340) and prasugrel (<jats:italic>n<\/jats:italic>\u2009=\u20091289). The pooled results showed that the prasugrel-treated patients had higher platelet reactivity than the ticagrelor-treated patients (PRU: WMD\u2009=\u2009\u2212\u200932.26; 95% CI: \u2212\u200956.48 to \u2212\u20098.76; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01; VASP-PRI: WMD\u2009=\u2009\u2212\u20099.61; 95% CI: \u2212\u200914.63 to \u2212\u20094.60; <jats:italic>P<\/jats:italic>\u2009=\u20090.002). No significant difference in HTPR based on PRU was identified between the ticagrelor and prasugrel groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.71), whereas a lower HTPR based on VASP-PRI was found in the ticagrelor-treated patients than in the prasugrel-treated patients (RR\u2009=\u20090.30; 95% CI: 0.12\u20130.75; <jats:italic>P<\/jats:italic>\u2009=\u20090.010). In addition, the results showed a lower LTPR was observed in the prasugrel group than in the ticagrelor group (RR\u2009=\u20091.40; 95% CI: 1.08\u20131.81; <jats:italic>P<\/jats:italic>\u2009=\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Prasugrel might enable higher platelet reactivity than ticagrelor. Ticagrelor could lead to a decrease in HTPR and increase in LTPR. However, this result was only obtained in pooled observational studies. Several uncertainties such as the nondeterminancy of the effectiveness of ticagrelor estimated using VASP-PRI or the definition of HTPR (a high or modifiable risk factor) might have affected our results.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-020-01603-0","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T13:03:53Z","timestamp":1601557433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1453-0948","authenticated-orcid":false,"given":"Mingxiang","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"issue":"Suppl 6","key":"1603_CR1","doi-asserted-by":"publisher","first-page":"s43","DOI":"10.7861\/clinmedicine.16-6-s43","volume":"16","author":"T Kotecha","year":"2016","unstructured":"Kotecha T, Rakhit RD. Acute coronary syndromes. Clin Med. 2016;16(Suppl 6):s43\u20138.","journal-title":"Clin Med"},{"issue":"4","key":"1603_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11883-014-0401-9","volume":"16","author":"CG Santos-Gallego","year":"2014","unstructured":"Santos-Gallego CG, Picatoste B, Badim\u00f3n JJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep. 2014;16(4):401.","journal-title":"Curr Atheroscler Rep"},{"issue":"21","key":"1603_CR3","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.115.021158","volume":"133","author":"A Bagai","year":"2016","unstructured":"Bagai A, Bhatt DL, Eikelboom JW, Mancini GJ, Cohen EA, Vijayaraghavan R, Cheema AN, Udell JA, Niznick J, Tanguay J-F. Individualizing duration of dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention. Circulation. 2016;133(21):2094\u20138.","journal-title":"Circulation"},{"issue":"1","key":"1603_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","volume":"12","author":"F Franchi","year":"2015","unstructured":"Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12(1):30\u201347.","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"1603_CR5","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1603_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"3","key":"1603_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","volume":"60","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012;60(3):193\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1603_CR8","first-page":"551","volume":"112","author":"D Alexopoulos","year":"2014","unstructured":"Alexopoulos D, Stavrou K, Koniari I, Gkizas V, Perperis A, Kontoprias K, Vogiatzi C, Bampouri T, Xanthopoulou I. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost. 2014;112(3):551\u20137.","journal-title":"Thromb Haemost"},{"issue":"8","key":"1603_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2337\/dc12-2510","volume":"36","author":"D Alexopoulos","year":"2013","unstructured":"Alexopoulos D, Xanthopoulou I, Mavronasiou E, Stavrou K, Siapika A, Tsoni E, Davlouros P. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes Care. 2013;36(8):2211\u20136.","journal-title":"Diabetes Care"},{"issue":"15","key":"1603_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.jacc.2013.11.032","volume":"63","author":"DJ Angiolillo","year":"2014","unstructured":"Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, Jakubowski JA, Zettler M, Effron MB, Trenk D. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (switching anti Platelet-2). J Am Coll Cardiol. 2014;63(15):1500\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1603_CR11","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.ijcard.2013.10.043","volume":"170","author":"P Deharo","year":"2013","unstructured":"Deharo P, Bassez C, Bonnet G, Pankert M, Quilici J, Lambert M, Verdier V, Morange P, Alessi M-C, Bonnet J-L. Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison. Int J Cardiol. 2013;170(2):e21\u20132.","journal-title":"Int J Cardiol"},{"issue":"3","key":"1603_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.ijcard.2014.07.228","volume":"176","author":"P Deharo","year":"2014","unstructured":"Deharo P, Pankert M, Bonnet G, Quilici J, Bassez C, Morange P, Alessi M-C, Bonnet J-L, Cuisset T. Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. Int J Cardiol. 2014;176(3):1200\u20132.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1603_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ijcard.2014.07.019","volume":"176","author":"J Dillinger","year":"2014","unstructured":"Dillinger J, Manzo SS, Amsallem M, Sideris G, Voicu S, Henry P, Drouet L. Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests. Int J Cardiol. 2014;176(2):557.","journal-title":"Int J Cardiol"},{"issue":"11","key":"1603_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jcin.2016.02.039","volume":"9","author":"F Franchi","year":"2016","unstructured":"Franchi F, Faz GT, Rollini F, Park Y, Cho JR, Thano E, Hu J, Kureti M, Aggarwal N, Durairaj A. Pharmacodynamic effects of switching from Prasugrel to Ticagrelor: results of the prospective, randomized SWAP-3 study. J Am Coll Cardiol Intv. 2016;9(11):1089\u201398.","journal-title":"J Am Coll Cardiol Intv"},{"issue":"10","key":"1603_CR15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.acvd.2015.04.004","volume":"108","author":"M Kerneis","year":"2015","unstructured":"Kerneis M, Silvain J, Abtan J, Hauguel M, Barth\u00e9l\u00e9my O, Payot L, Brugier D, Galier S, Collet J-P, Montalescot G. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. Arch Cardiovasc Dis. 2015;108(10):502\u201310.","journal-title":"Arch Cardiovasc Dis"},{"issue":"2","key":"1603_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1160\/TH13-05-0384","volume":"111","author":"M Laine","year":"2014","unstructured":"Laine M, Frere C, Toesca R, Berbis J, Barnay P, Pansieri M, Michelet P, Bessereau J, Camilleri E, Ronsin O. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thromb Haemost. 2014;111(2):273\u20138.","journal-title":"Thromb Haemost"},{"issue":"6","key":"1603_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3109\/09537104.2014.959914","volume":"26","author":"M Laine","year":"2015","unstructured":"Laine M, Gaubert M, Fr\u00e8re C, Peyrol M, Thuny F, Yvorra S, Chelini V, Bultez B, Luigi S, Mokrani Z. COM parison of P latelet reactivity following pr a sugrel and ticagrelor loading dose in S T-S egment elevation myocardial infarctI ON patients: the COMPASSION study. Platelets. 2015;26(6):570\u20132.","journal-title":"Platelets"},{"issue":"3","key":"1603_CR18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ijcard.2014.04.208","volume":"174","author":"T Lhermusier","year":"2014","unstructured":"Lhermusier T, Voisin S, Murat G, Mejean S, Garcia C, Bataille V, Lipinski M, Carrie D, Sie P. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. Int J Cardiol. 2014;174(3):874\u20136.","journal-title":"Int J Cardiol"},{"issue":"15","key":"1603_CR19","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","volume":"61","author":"G Parodi","year":"2013","unstructured":"Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol. 2013;61(15):1601\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijcard.2015.05.085","volume":"194","author":"G Sardella","year":"2015","unstructured":"Sardella G, Calcagno S, Mancone M, Lucisano L, Pennacchi M, Stio RE, Placentino F, Di Roma A, Cavallo E, Palmirotta R. Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial. Int J Cardiol. 2015;194:60\u20132.","journal-title":"Int J Cardiol"},{"issue":"5","key":"1603_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/imj.13041","volume":"46","author":"MB Yudi","year":"2016","unstructured":"Yudi MB, Clark DJ, Farouque O, Eccleston D, Andrianopoulos N, Duffy SJ, Brennan A, Lefkovits J, Ramchand J, Yip T. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J. 2016;46(5):559\u201365.","journal-title":"Intern Med J"},{"key":"1603_CR22","doi-asserted-by":"crossref","unstructured":"Sch\u00fcpke S, Neumann F-J, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524\u201334.","DOI":"10.1056\/NEJMoa1908973"},{"issue":"6","key":"1603_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/jth.12907","volume":"13","author":"G Lemesle","year":"2015","unstructured":"Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost. 2015;13(6):931\u201342.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1603_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/MCA.0000000000000541","volume":"28","author":"H Zhang","year":"2017","unstructured":"Zhang H, Zhang P, Dong P, Yang X, Wang Y, Zhang H, Yan J, Zhang Y, Zhang T, Li Y. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis. Coron Artery Dis. 2017;28(7):597\u2013604.","journal-title":"Coron Artery Dis"},{"issue":"4","key":"1603_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"key":"1603_CR26","volume-title":"3rd Symposium on Systematic Reviews: Beyond the Basics Oxford, Engiand","author":"G Well","year":"2000","unstructured":"Well G, Shea B, O\u2019COnnell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Heath Research Institute. In:  3rd Symposium on Systematic Reviews: Beyond the Basics Oxford, Engiand, vol. 2000; 2000."},{"issue":"7414","key":"1603_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557\u201360.","journal-title":"Br Med J"},{"key":"1603_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijcard.2016.12.173","volume":"230","author":"LF Guimar\u00e3es","year":"2017","unstructured":"Guimar\u00e3es LF, G\u00e9n\u00e9reux P, Silveira D, Pesaro AE, Falc\u00e3o F, Barbosa BR, de Souza CF, Fonseca FA, Alves CM, Carvalho AC, Stone GW, Caixeta A. P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: analysis from the SAMPA randomized trial. Int J Cardiol. 2017;230:204\u20138.","journal-title":"Int J Cardiol."},{"issue":"9","key":"1603_CR29","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S Husted","year":"2006","unstructured":"Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038\u201347.","journal-title":"Eur Heart J"},{"issue":"9","key":"1603_CR30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","volume":"63","author":"L Bonello","year":"2014","unstructured":"Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63(9):872\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1603_CR31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.thromres.2007.07.002","volume":"121","author":"MD Linden","year":"2008","unstructured":"Linden MD, Barnard MR, Frelinger AL, Michelson AD, Przyklenk K. Effect of adenosine a 2 receptor stimulation on platelet activation\u2013aggregation: differences between canine and human models. Thromb Res. 2008;121(5):689\u201398.","journal-title":"Thromb Res"},{"issue":"10","key":"1603_CR32","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","volume":"27","author":"T Jernberg","year":"2006","unstructured":"Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166\u201373.","journal-title":"Eur Heart J"},{"issue":"6","key":"1603_CR33","first-page":"441","volume":"3","author":"S Ederhy","year":"2007","unstructured":"Ederhy S. TRITON-TIMI 38 investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. MT Cardiol. 2007;3(6):441\u20133.","journal-title":"MT Cardiol"},{"issue":"9711","key":"1603_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(10)60070-0","volume":"375","author":"GW Stone","year":"2010","unstructured":"Stone GW. Ticagrelor in ACS: redefining a new standard of care? Lancet. 2010;375(9711):263\u20135.","journal-title":"Lancet"},{"issue":"7","key":"1603_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/09537104.2013.840363","volume":"25","author":"G Lemesle","year":"2014","unstructured":"Lemesle G, Landel J-B, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche J-M. Poor agreement between light transmission aggregometry, Verify now P2Y12 and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials. Platelets. 2014;25(7):499\u2013505.","journal-title":"Platelets"},{"issue":"12","key":"1603_CR36","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1603_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jcin.2012.10.007","volume":"6","author":"JL Ferreiro","year":"2013","unstructured":"Ferreiro JL, Ueno M, Tello-Montoliu A, Tomasello SD, Seecheran N, Desai B, Rollini F, Guzman LA, Bass TA, Angiolillo DJ. Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy. J Am Coll Cardiol Intv. 2013;6(2):182\u20134.","journal-title":"J Am Coll Cardiol Intv"},{"issue":"1","key":"1603_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.bjp.0703045","volume":"129","author":"S Gessi","year":"2000","unstructured":"Gessi S, Varani K, Merighi S, Ongini E, Borea P. A2A adenosine receptors in human peripheral blood cells. Br J Pharmacol. 2000;129(1):2\u201311.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1603_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","volume":"8","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Sch\u00f6mig A, Von Beckerath N, Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost. 2010;8(2):250\u20136.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1603_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3109\/09537104.2015.1095874","volume":"27","author":"JM Siller-Matula","year":"2016","unstructured":"Siller-Matula JM, Akca B, Neunteufl T, Maurer G, Lang IM, Kreiner G, Berger R, Delle-Karth G. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets. 2016;27(4):373\u20137.","journal-title":"Platelets"},{"issue":"8","key":"1603_CR41","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1080\/09537104.2016.1190007","volume":"27","author":"I Bernlochner","year":"2016","unstructured":"Bernlochner I, Mayer K, Orban M, Morath T, Jaitner J, R\u00f6ssner L, Gross L, Laugwitz K-L, Kastrati A, Sibbing D. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: the ISAR-ADAPT-PF study. Platelets. 2016;27(8):796\u2013804.","journal-title":"Platelets"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01603-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01603-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01603-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T01:19:44Z","timestamp":1633051184000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01603-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01603-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"28 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"430"}}